UNSPSC 51262004: Moxisylyte

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C16H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PW8QYA7KI0, chemically known as phenol, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)-, acetate (ester) but generally known as moxisylyte, which bears US NIH Compound Identifier 4260. European Medicines Agency schedules Moxisylyte in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09090MIG.

UNSPSC 51262004 Moxisylyte, a Commodity code, nominally refers to a specific pharmaceutical agent, but recent state and local procurement activity under this code shows substantial mismatch — the two most recent opportunities are actually purchasing naloxone (an opioid antagonist used in overdose response) and conducting market research on direct-to-manufacturer prescription programs, neither of which is moxisylyte. State and local governments appear to be tagging health-related pharmaceutical procurement and pharmacy benefit program initiatives under this code, suggesting either miscoding in source systems or use of the code as a catch-all for specialized pharmaceutical products and services. The Seminole County, Florida purchase is a concrete example: the county is procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding to support community health initiatives, with quarterly deliveries required and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission, meanwhile, is in an exploratory phase via RFI, seeking vendor capabilities around direct contracting between the state's pharmacy benefit program and manufacturers outside traditional pharmacy benefit managers and group purchasing organizations.

The geographic spread is limited in recent activity. Florida and Texas each appear once; no other states are represented in the available opportunities. Seminole County (IFB60459723LAS, due July 26, 2023) is the only concrete procurement opportunity, while the Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) is a market-research vehicle rather than a formal solicitation. The mismatch between the code's nominal scope and actual purchasing activity, combined with the sparse recent opportunity record, suggests this code sees little activity in state and local procurement and may not be a reliable indicator of current market demand for pharmaceutical products or services.